AI Summary Sandostatin (octreotide) is a synthetic somatostatin analogue given by injection, usually short term, as part of combination therapy with albumin and midodrine for hepatorenal syndrome.
Medically reviewed.
Sandostatin (octreotide) is a synthetic somatostatin analogue that healthcare providers use as part of combination therapy for hepatorenal syndrome (HRS), which is worsening kidney function related to advanced liver disease, and for complications of portal hypertension. It helps change blood flow within the abdominal circulation, and it is often given together with albumin and midodrine. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Sandostatin's role in hepatorenal syndrome care — how it works, who may be eligible, what treatment involves, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Sandostatin fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT SANDOSTATIN TREATMENT
Sandostatin is a brand name for octreotide, a synthetic somatostatin analogue. It is a lab-made medicine that acts like somatostatin, a natural substance in the body.
Healthcare providers use octreotide as part of combination therapy for hepatorenal syndrome (HRS), which is worsening kidney function related to advanced liver disease. It is also used for complications of portal hypertension, which is high pressure in the veins that carry blood through the liver.
Octreotide helps change blood flow within the abdominal circulation. It may improve treatment outcomes when it is combined with albumin infusion and midodrine (ProAmatine). It is given as an injection under medical supervision.
WHO SANDOSTATIN MAY BE SUITABLE FOR
Eligibility for Sandostatin depends on your diagnosis, your kidney function, and your overall health. Your healthcare provider may prescribe it if you have hepatorenal syndrome, need combination vasoconstrictor therapy, have complications of portal hypertension, or need additional circulatory support.
A vasoconstrictor is a medicine that tightens blood vessels. Sandostatin is often used alongside other vasoconstrictor and volume-support treatments, such as midodrine and albumin.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Sandostatin. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Sandostatin may be considered for adults with the following conditions or treatment needs:
Before recommending Sandostatin, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW SANDOSTATIN CAN HELP YOUR KIDNEYS
Sandostatin reduces blood flow within the splanchnic circulation, which is the blood supply to the digestive organs in the abdomen. This helps improve effective blood volume, which is the amount of blood that is working to supply your vital organs.
With better circulation, blood flow to the kidneys (kidney perfusion) may improve. Octreotide also complements the effects of midodrine, which is why the two medicines are often used together.
For people with hepatorenal syndrome, these effects support treatment goals such as better kidney blood flow and stabilization of kidney function. Sandostatin is not used on its own. Providers combine it with albumin and midodrine and monitor kidney function, blood pressure, and treatment response regularly.
LIVER BENEFITS
Sandostatin (octreotide) is a synthetic somatostatin analogue. It reduces blood flow within the splanchnic circulation, which is the blood supply to the digestive organs in the abdomen. This is how it helps alter blood flow when complications of advanced liver disease affect your circulation.
Effective blood volume is the amount of blood that is actively supplying your vital organs. By changing blood flow in the abdomen, Sandostatin helps improve this volume. Your care team may add it to your plan when you need additional circulatory support.
Hepatorenal syndrome (HRS) is worsening kidney function related to advanced liver disease. With better circulation, blood flow to the kidneys, called kidney perfusion, may improve. This supports treatment goals such as stabilizing kidney function.
Portal hypertension is high pressure in the veins that carry blood through the liver. Sandostatin is also used for complications that come with it. Your provider decides whether it fits your situation after reviewing your diagnosis and overall health.
Sandostatin supports liver care by changing abdominal blood flow, improving effective blood volume, and helping maintain blood flow to the kidneys in advanced liver disease. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Sandostatin is supplied as an injection that is given under the skin (subcutaneous) or into a vein (intravenous). Your care team prepares and gives it.
Your healthcare provider sets the dose based on your condition and how your kidneys respond. It is often used together with albumin and midodrine. Do not change your dose without medical guidance.
Sandostatin is given by subcutaneous or intravenous injection under medical supervision, following a scheduled dosing plan.
Treatment is usually short-term and continues for several days to weeks, depending on your kidney response and stabilization. It is typically continued until kidney function improves, a transplant is performed, or another management plan is started. Your care team reassesses treatment throughout.
Store Sandostatin according to the manufacturer's recommendations. Ask your pharmacist or care team if you have questions.
Your healthcare team regularly monitors kidney function, blood pressure, and how you respond to treatment. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Sandostatin (octreotide) may support people with hepatorenal syndrome by improving circulation and blood flow to the kidneys. It is often used as part of combination therapy with albumin and midodrine, and this combination may improve treatment outcomes. The extent of these benefits varies from person to person, depending on liver condition, kidney function, and how the body responds to therapy.
Sandostatin is not a stand-alone treatment. It works best as part of a broader, personalized care plan with ongoing monitoring of kidney function and blood pressure.
As with any medication, Sandostatin may cause side effects, ranging from digestive symptoms to injection-site reactions and changes in blood sugar levels. Your healthcare provider will monitor your response throughout treatment and assess whether Sandostatin remains a suitable option for you.
BENEFITS
If your care team decides you need additional circulatory support, Sandostatin is one option they may add to your plan. It helps optimize blood flow, and it may be used for hepatorenal syndrome or for complications of portal hypertension.
Sandostatin fits into a combination plan. It is often used with midodrine and albumin, and the combination may improve treatment outcomes. Because it is given by injection under medical supervision, your care team handles each dose and decides which medicines make up your plan.
The goal for most people is steadier kidney function. Sandostatin may improve renal perfusion, which is blood flow to the kidneys, but the benefit varies from person to person. Regular checks of kidney function and blood pressure show how you are responding.
Sandostatin supports the treatment of hepatorenal syndrome for a limited time. Treatment usually lasts several days to weeks. It continues until kidney function improves, a transplant is performed, or another plan begins, and your team reassesses it throughout.
Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including monitoring of kidney function and blood pressure, to help ensure safe use.
SUPPORTING YOUR RESULTS
Sandostatin works best alongside steady self-care. Follow any sodium and fluid recommendations from your healthcare team, avoid alcohol, and take your medications consistently as prescribed.
Monitor your daily weight if you are advised to, and attend all follow-up appointments for laboratory and blood pressure monitoring. These habits help your care team track how you respond to treatment.
Areas that may support treatment:
COMMON QUESTIONS
No, Sandostatin is not a cure for hepatorenal syndrome. Providers use it as part of combination therapy, usually with albumin and midodrine, to support circulation and blood flow to the kidneys. Treatment is usually short-term and may continue until kidney function improves, a transplant is performed, or another management plan is started. Results vary from person to person. Talk with your healthcare provider about realistic goals for your care plan.
Sandostatin may be considered for people with hepatorenal syndrome, which is worsening kidney function related to advanced liver disease. Your provider may also prescribe it if you need combination vasoconstrictor therapy, have complications of portal hypertension, or need additional circulatory support. Whether it fits depends on your diagnosis, kidney function, and overall health. Only a qualified healthcare professional can decide if Sandostatin is right for you, so ask your care team about your situation.
Sandostatin is given as an injection, either under the skin (subcutaneous) or into a vein (intravenous), under medical supervision. Your care team follows a scheduled dosing plan and sets the dose based on your condition and how your kidneys respond. Do not change your dose without medical guidance. Store the medicine according to the manufacturer's recommendations, and ask your pharmacist or care team if you have questions about handling it.
Sandostatin treatment is usually short-term, lasting several days to weeks, depending on your kidney response and stabilization. It is typically continued until kidney function improves, a transplant is performed, or another management plan is started. Your care team reassesses treatment throughout and regularly monitors your kidney function, blood pressure, and response. Your provider can explain what timeline to expect for you based on how your body responds.
Common side effects of Sandostatin include nausea, abdominal pain, diarrhea, injection-site reactions, and changes in blood sugar levels. Your healthcare team regularly monitors your kidney function, blood pressure, and treatment response to help ensure safe use. Report any side effects or unusual symptoms to your provider. Your provider will discuss the potential benefits and risks with you before treatment, so ask about what to watch for.
Sandostatin is combined with albumin and midodrine because the combination may improve treatment outcomes in hepatorenal syndrome. Octreotide reduces blood flow in the abdominal circulation, which helps improve effective blood volume and kidney perfusion, and it complements the effects of midodrine. Your provider decides which medicines make up your plan. Ask your healthcare professional how each medicine fits your care and what results to expect.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
